ViTrax

What ViTrax does

ViTrax is a Placentia, California-based specialty manufacturer of radiolabeled chemicals for the pharmaceutical and biotechnology research industries. The company produces isotopically labeled compounds using four radioisotopes—Tritium (H-3), Carbon-14 (C-14), Iodine-125 (I-125), and Sulfur-35 (S-35)—for applications including drug metabolism studies, pharmacokinetic analysis, receptor binding assays, and biomedical research. Its product portfolio comprises a catalog of 300+ compounds alongside custom synthesis services, GMP-compliant manufacturing (with a dedicated synthesis lab and Class 10,000 cleanroom), and analytical support services including HPLC, NMR, and GC analysis.

The company's underlying technology is rooted in radiochemical synthesis techniques such as catalytic reduction with tritium gas, sodium borohydride and lithium aluminum hydride reductions, catalytic exchange, alkylation with methyl iodide, and radioiodination. ViTrax serves three primary customer segments—pharmaceutical companies (primary), academic and research institutions, and biotechnology companies—with horizontal segmentation across all groups.

ViTrax operates a sales-led, direct distribution model with a website-based catalog and quote request system. Pricing is quote-based and not publicly disclosed, with each custom synthesis project priced individually based on scale, complexity, reagent type, and analysis method. Revenue is generated through one-time catalog product sales and professional services revenue from custom synthesis and analytical testing. The company ships globally with specialized radioactive material handling, including overnight dry ice delivery for tritium products. ViTrax is a privately held corporation with no disclosed funding history, no parent company, and 1-10 employees per firmographic data.

Name

ViTrax

Legal name

ViTrax, Inc.

Website

https://vitrax.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

ViTrax is a Placentia, California-based specialty manufacturer of radiolabeled chemicals (Tritium, Carbon-14, Iodine-125, Sulfur-35) and GMP radiosynthesis services for pharmaceutical, biotechnology, and academic research customers. It sells a 300+ compound catalog and offers custom synthesis and analytical support.

Ownership category

akta.pro rank

Product category

Radiolabeled Specialty Chemicals

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Chemical Manufacturing (325)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industry

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)

Keywords

• Radiolabeled chemicals
• Custom radiochemical synthesis
• GMP radiochemical manufacturing
• Isotope labeling services
• Tritium carbon-14 compounds

Headquarters

HQ city

Placentia

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Radiochemical Product Sales: Sale of catalog radiochemical products including Tritium-labeled, Carbon-14-labeled, and Iodine-125-labeled compounds. Products are used in pharmaceutical research, drug discovery, and analytical applications.
2. Custom Synthesis Services: Bespoke radiochemical synthesis services for specific customer compounds. Includes tritium labeling, carbon-14 synthesis, iodine-125 labeling, and sulfur-35 synthesis services with project-specific pricing.
3. Analytical Services: Method development and analytical testing services for radioactive and non-radioactive compounds including HPLC, NMR, GC analysis, and radioactivity quantification.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

ViTrax manufactures and supplies radiolabeled chemical compounds incorporating Tritium (3H), Carbon-14 (14C), Iodine-125 (125I), and Sulfur-35 (35S) isotopes for pharmaceutical, biotechnology, and academic research. The company operates an online catalog of 300+ radiochemical products, performs custom radiosynthesis projects, and provides GMP-compliant radiochemical manufacturing in a Class 10,000 cleanroom with associated analytical testing services.

Product overview

ViTrax is a specialized radiochemical company offering a comprehensive portfolio of radiolabeled compounds and synthesis services. The core offerings center on three radioisotope product lines—Tritium (3H), Carbon-14 (14C), and Iodine-125 (125I) labeled compounds—sold through an online catalog. These are complemented by Custom Synthesis Services for bespoke radiolabeling projects, GMP manufacturing capabilities, Tritium Labeling Services, and Analytical Support Services. The company serves pharmaceutical, biotechnology, and research institutions requiring isotopically labeled chemicals for drug discovery, metabolism studies, and biomedical research applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Tritium Labeled Compounds (3H)
• Carbon-14 Labeled Compounds (14C)
• Iodine-125 Labeled Compounds (125I)
• Custom Radiosynthesis Services
• Analytical Support Services
• GMP Radiochemical Manufacturing

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators3 records

Recent moves5 records

Expansion highlights3 records

Broad incumbents

• Cytiva: Cytiva (formerly GE Healthcare Life Sciences) supplies research tools including radiolabeled compounds, chromatography, and lab services for pharma and biotech research. It is a broad incumbent that competes with ViTrax in select research radiochemical products as part of a much larger portfolio.
• Revvity: Revvity (formerly PerkinElmer Life Sciences) is a large life sciences tools and radiolabeled compounds provider with broad product portfolios in radiolabeled chemicals, scintillation products, and nuclear medicine. It offers overlapping catalog products alongside much wider capability and scale.
• Pharmaron: Pharmaron acquired Quotient Bioresearch, a major radiolabeled compound and ADME services provider. The combined entity offers radiolabeling plus broader drug discovery CDMO services, representing a larger scaled competitor with overlapping radiochemistry capabilities.
• Sigma-Aldrich (Merck KGaA): Sigma-Aldrich (a Merck KGaA business) supplies a broad catalog of research chemicals including select radiolabeled compounds. It competes with ViTrax on catalog products for academic and pharmaceutical research as part of a much larger specialty chemicals portfolio.

Emerging players

• Selvita: Selvita is a Polish contract research organization providing drug discovery and custom chemistry services for pharmaceutical clients, with capabilities overlapping ViTrax's custom synthesis and analytical support offerings for small to mid-size pharma research programs.
• Novandi Chemistry: Novandi is a custom synthesis provider with capabilities in radiochemistry and radiolabeled compound manufacturing for pharmaceutical research customers, representing an emerging alternative in the custom radiochemical synthesis space comparable to ViTrax.

Direct peers

• ABX Advanced Biochemical Compounds: ABX is a German manufacturer of radiolabeled compounds and PET precursor chemicals serving pharmaceutical research and nuclear medicine, with overlapping capabilities to ViTrax in radiochemical synthesis for research and clinical applications.
• Moravek Biochemicals: Moravek specializes in custom radiosynthesis and catalog radiolabeled compounds (C-14, H-3, S-35) for biomedical research, with GMP capabilities and a customer base in pharma and academia, making it a highly comparable specialty radiochemical supplier to ViTrax.
• American Radiolabeled Chemicals (ARC): ARC is a US-based specialty manufacturer offering custom radiosynthesis and a catalog of C-14, H-3, S-35, and I-125 labeled compounds for pharmaceutical and academic research. It is the closest direct peer to ViTrax with a highly comparable product mix and customer base.

Regional players

• IBA (Ion Beam Applications): IBA is a Belgium-based leader in cyclotron and radioisotope production equipment, with growing involvement in radiopharmaceutical production. While primarily a technology provider, it represents a regional player with adjacent capabilities in radiochemistry and isotope supply.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vitrax-radiochemicals

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ViTrax